NCT06804655 (EViDENCE-BT) is a Phase 2 clinical trial of Pharmacoscopy 1.0 in Brain (Nervous System) Cancers, sponsored by University of Zurich.

Who is sponsoring NCT06804655?

NCT06804655 is sponsored by University of Zurich.

What drugs are being tested in NCT06804655?

Interventions in NCT06804655: Pharmacoscopy 1.0.

What condition does NCT06804655 study?

NCT06804655 studies Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma, Medulloblastoma, Meningioma, Rare Primary Brain Tumors, Rare CNS Primary Tumors.

Is NCT06804655 still recruiting?

NCT06804655 is currently not yet recruiting. Last updated 2 October 2025.

Last reviewed 2025-10-02 · How we verify

NCT06804655: EViDENCE-BT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

Not yet recruiting Phase 2 Last updated 2 October 2025

What this trial tests

Phase 2 trial testing Pharmacoscopy 1.0 in Brain (Nervous System) Cancers in 40 participants. Not yet recruiting.

Timeline

12 February 2026

Primary endpoint
15 September 2028

15 September 2028

Quick facts

Lead sponsor	University of Zurich
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	40
Start date	12 February 2026
Primary completion	15 September 2028
Estimated completion	15 September 2028
Sites	3 locations across Switzerland

Drugs / interventions tested

Pharmacoscopy 1.0

Conditions studied

Brain (Nervous System) Cancers — all drugs for Brain (Nervous System) Cancers →
Glioblastoma — all drugs for Glioblastoma →
Glioma — all drugs for Glioma →
Ependymoma — all drugs for Ependymoma →

Sponsor

University of Zurich

Who can join

18 and older, any sex, with Brain (Nervous System) Cancers or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors.
Adefolaju A, Kram DE, Mann B, Hingtgen S, et al · · 2026 · PMID 41270976 · DOI 10.1016/j.addr.2025.115736

Verify or expand the search:

Other recruiting trials for Brain (Nervous System) Cancers

Currently open trials in the same condition.

NCT07126821 — A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data · recruiting
NCT05859659 — Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE) · recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06804655 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 2 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06804655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing